Search results
Results from the WOW.Com Content Network
While heparin was introduced for clinical use in the late 1930s, new thrombosis in people treated with heparin was not described until 1957, when vascular surgeons reported the association. [ 4 ] [ 16 ] The fact that this phenomenon occurred together with thrombocytopenia was reported in 1969; [ 17 ] prior to this time, platelet counts were not ...
Heparin is an anticoagulant, and if used as a catheter lock solution it could leak into the blood circulation of the patient. Therefore it has been associated with catheter-related bleeding and heparin induced thrombocytopenia (HIT). [8] [9] Citrate catheter lock solutions are being used in three different concentrations – 4%, 30% and 46.7%.
Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. [3] [4] Heparin is a blood anticoagulant that increases the activity of antithrombin. [5] It is used in the treatment of heart attacks and unstable angina. [3] It can be given intravenously or by injection under the skin. [3]
Taurolidine/heparin, sold under the brand name Defencath, is a fixed-dose combination catheter lock solution used for central venous catheter instillation. [ 1 ] [ 2 ] It contains taurolidine , a thiadiazinane antimicrobial; and heparin , an anti-coagulant .
In children, the most common cause is a stroke of the ventral pons. [9]Unlike persistent vegetative state, in which the upper portions of the brain are damaged and the lower portions are spared, locked-in syndrome is essentially the opposite, caused by damage to specific portions of the lower brain and brainstem, with no damage to the upper brain.
Average molecular weight: heparin is about 15 kDa, and LMWH is about 4.5 kDa. [25] Less frequent subcutaneous dosing than for heparin for postoperative prophylaxis of venous thromboembolism. Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high-dose heparin.
Depending on the thrombolytic agent being used, additional anticoagulation with heparin or low molecular weight heparin may be of benefit. [ 11 ] [ 12 ] With tPa and related agents (reteplase and tenecteplase), heparin is needed to keep the coronary artery open.
Heparin remains one of the most effective anticoagulants and is still used today, although it has its disadvantages, such as requiring intravenous administration and having a variable dose-response curve due to substantial protein binding. [4] In the 1980s low molecular-weight heparin (LMWH) were developed.